RxDoctor Payments Data

Stephanie Ruffin, NP

Psychiatric/Mental Health · Meridian, MSNPI 1124791512

Payments from drug & device makers

$1,600in general payments, 2019–2025

Across 55 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$444
  • AbbVie$443
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$253
  • Otsuka America Pharmaceutical, Inc.$193
  • Neurocrine Biosciences, Inc.$124
  • Novo Nordisk$57
  • plus $86 from 3 others

What the payments were for

  • Food & beverage$1,594100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,600 in reported general payments places this provider in the 65th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$144,769
Medicare patients
442
Services billed
2,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate27$95,081
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl268$32,214
RexultiBrexpiprazole22$15,687
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$8,526
Rivastigmine33$5,563
Memantine Hcl43$3,583
Chlorpromazine Hcl19$3,414
Trazodone Hcl275$2,242
Oxcarbazepine62$2,040
Buspirone Hcl113$1,696
Haloperidol Decanoate15$1,380
Olanzapine62$1,319
Vilazodone Hcl12$1,170
Doxepin Hcl83$1,169
Paliperidone ErPaliperidone12$1,054

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$193$15,68722 claims
Indivior Inc.Suboxone$39$8,52613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →